Skip to main content

Table 1 Baseline characteristics of patients with metastatic ccRCC treated with subsequent therapy after discontinuation of IO-VEGF

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Patient and tumor characteristics

Entire cohort (N = 59)

aPatients included in theefficacy analysis (N = 55)

Age at diagnosis (years) – median (range)

55 (33–75)

55 (33–75)

Male gender

46 (78%)

43 (78%)

Prior nephrectomy

56 (95%)

52 (95%)

Prior IO-VEGF combination by category

 IO-Bev

35 (59%)

33 (60%)

 IO-TKI

24 (41%)

22 (40%)

Prior IO-VEGF combinations by regimen

 Atezolizumab and bevacizumab

34 (58%)

32 (58%)

 Avelumab and axitinib

12 (20%)

11 (20%)

 Pembrolizumab and lenvatinib

8 (14%)

7 (13%)

 Pembrolizumab and pazopanib

2 (3%)

2 (3%)

 Pembrolizumab and axitinib

1 (2%)

1 (2%)

 Nivolumab and sunitinib

1 (2%)

1 (2%)

 Nivolumab and bevacizumab

1 (2%)

1 (2%)

Reason for discontinuation of IO-VEGF

 Progression of disease

55 (93%)

51 (93%)

 Toxicity

3 (5%)

3 (5%)

 Other

1 (2%)

1 (2%)

Time from discontinuation of IO-VEGF to start of the next line therapy (days) - median (range)

28 (3–574)

30 (3–615)

IMDC risk at the start of next line of therapy

 Favorable

13 (22%)

11 (20%)

 Intermediate

35 (59%)

33 (60%)

 Poor

11 (19%)

11 (20%)

Post IO-VEGF next line of therapy

 Cabozantinib

22 (37%)

22 (40%)

 Axitinib

18 (31%)

18 (33%)

 Pazopanib

4 (7%)

4 (7%)

 Lenvatinib and everolimus

4 (7%)

4 (7%)

 mTOR inhibitor monotherapy

3 (5%)

3 (5%)

 Axitinib and dalantercept (Clinical trial)

2 (3%)

2 (4%)

 Sunitinib

1 (2%)

1 (2%)

 Sorafenib

1 (2%)

1 (2%)

 Unreported clinical trials

4 (7%)

–

Number of therapy line post IO-VEGF

 Second

42 (71%)

39 (71%)

 Third

17 (29%)

16 (29%)

  1. Abbreviations: IO-VEGF Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy, IO-Bev Immune-Oncology and Bevacizumab, IO-TKI Immune-Oncology and Tyrosine Kinase Inhibitor, IMDC International Metastatic Database Consortium, VEGFR-TKI Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor, mTOR Mammalian Target of Rapamycin
  2. aPatients enrolled on unreported clinical trials were excluded from the efficacy analysis